Abstract: Hypoglycaemia remains the main limiting factor in type 1 diabetes management. We developed an insulin-dependent glucagon dosing regimen for treatment of mild hypoglycaemia based on simulations. A validated glucose-insulin-glucagon model was used to describe seven virtual patients with insulin pump-treated type 1 diabetes. In each simulation, one of ten different and individualized subcutaneous insulin boluses was administered to decrease plasma glucose (PG) from 7.0 to ≤3.9 mmol/l. Insulin levels were estimated as ratio of actual to baseline serum insulin concentration (se/ba-insulin), insulin on board (IOB) or percentage of IOB to total daily insulin dose (IOB/TDD). Insulin bolus sizes were chosen to provide pre-defined insulin levels when PG reached 3.9 mmol/l, where one of 17 subcutaneous glucagon boluses was administered. Optimum glucagon bolus to treat mild hypoglycaemia at varying insulin levels was the lowest dose that in most patients caused PG peak between 5.0 and 10.0 mmol/l and sustained PG ≥ 3.9 mmol/l for 2 hr after the bolus. PG response to glucagon declined with increasing insulin levels. The glucagon dose to optimally treat mild hypoglycaemia depended exponentially on insulin levels, regardless of how insulin was estimated. A 125-lg glucagon dose was needed to optimally treat mild hypoglycaemia when insulin levels were equal to baseline levels. In contrast, glucagon doses >500 lg were needed when se/ba-insulin >2.5, IOB >2.0 U or IOB/TDD >6%. Although the proposed model-based glucagon regimen needs confirmation in clinical trials, this is the first attempt to develop an insulin-dependent glucagon dosing regimen for treatment of insulin-induced mild hypoglycaemia in patients with type 1 diabetes.
Intensive insulin therapy increases the risk of hypoglycaemia in patients with type 1 diabetes [1] . The fear of hypoglycaemia impedes many in seeking optimum glycaemic control and affects their quality of life negatively [2] . In recent years, treatment of type 1 diabetes has changed significantly with more frequent use of advanced insulin pumps, continuous glucose monitors and even a combination of these that allows insulin pumps to suspend their infusion as a response to present or pending hypoglycaemia [3] . Even devices with automated glucose control with or without meal announcements (closed-loop systems) have been developed but are not yet commercially available [4] . The insulin-only closed-loop system seems, at least in daytime and during exercise, to be inferior to the dual-hormone closed-loop system with the optional glucagon dosing [5, 6] . In both closed-loop systems, hypoglycaemia events were reduced compared to available treatment options, although not completely avoided [7] . Further, these systems increase treatment complexity and may be very costly, that is two hormones, two infusion catheters, and two chamber hormone pumps [8] . Our hypothesis was therefore that minidose glucagon could equally be injected manually as an alternative to oral carbohydrate intake in case of mild or impeding hypoglycaemia (open-loop system) [9, 10] . Glucagon may replace the extra calorie intakes involved with hypoglycaemia management and reduce the rising incidence of overweight and obesity in patients with type 1 diabetes [11] . A fixed glucagon dose may, however, not provide ideal glucose excursions especially when not accounting for, ambient insulin levels and exercise.
To our knowledge, a proposal for optimum dosing of glucagon to treat mild hypoglycaemia in an open-loop setting has never been developed for patients with type 1 diabetes. Although the antihypoglycaemic effect of glucagon highly depends on ambient insulin levels, no commercially available devices are able to measure insulin concentrations in real time [12] .
Bolus calculators in insulin pumps have addressed this issue by providing 'insulin on board' (IOB) feedback to reduce the risk of insulin stacking and hypoglycaemia [13] [14] [15] . Basal insulin is not included in the calculation of IOB, which is an approximation of the remaining effect of an insulin bolus, measured in units of subcutaneously (SC) administered bolus insulin [14] . Even patients on injection therapy often use bolus calculators to determine bolus insulin for a certain meal and/or a blood glucose level [16] . If bolus calculators were upgraded with an algorithm for mini-dosing of glucagon, patients would ideally receive suggestions on how to optimally treat mild or impeding hypoglycaemia, as the system can account for the IOB.
Based on simulations using pharmacokinetic (PK) and pharmacodynamic (PD) models for glucose, insulin and glucagon, our aim was to develop an optimum glucagon dosing regimen for treatment of mild hypoglycaemia depending on ambient insulin levels. We used a validated glucoregulatory model to simulate how different insulin levels would affect the glucose response to different glucagon doses [17] . The success of each glucagon dose in treating mild hypoglycaemia was evaluated. However, no consensus exists on optimal post-treatment glucose excursions. Our criteria for the optimum glucagon dose to treat mild hypoglycaemia at varying insulin levels were the lowest dose that in most patients caused a plasma glucose concentration (PG) peak between 5.0 and 10.0 mmol/l and sustained PG above or equal to 3.9 mmol/l for 2 hr after the bolus.
Methods

Data.
We used insulin and glucagon PK models in combination with a validated glucose-insulin-glucagon PD model to simulate data from seven virtual type 1 diabetes patients [17] . The model parameter vectors for the seven patients were identical to those presented by Wendt et al. [17] . MATLAB 2016b (The MathWorks, Inc., Natick, MA, USA) was used for model implementation and simulations.
The population of virtual patients described seven 'real' adults (four females, age range: 19-64 years, BMI range: 20.0-25.4 kg/m 2 ) with insulin pump-treated type 1 diabetes, who previously had participated in a study investigating the glucose response to different mini-doses of glucagon during insulin-induced mild hypoglycaemia [18] . Patients were in good glycaemic control (HbA1c range: 6.1-7.4%) and had no endogenous insulin production [18] . The PD model is an extension of Hovorka's glucoregulatory model with the effects of glucagon on the endogenous glucose production [19] and was validated in a previous study [17] . The PK models assumed that changes in insulin and glucagon concentrations were only due to the administered drugs: insulin aspart (NovoRapidâ; Novo Nordisk, Bagsvaerd, Denmark) and glucagon (GlucaGenâ; Novo Nordisk, Bagsvaerd, Denmark).
In silico experiments. We executed three simulations to investigate the glucose response to different glucagon doses depending on the ambient insulin levels during insulin-induced mild hypoglycaemia ( fig. 1) . In each simulation, a SC insulin bolus was administered at PG of 7.0 mmol/l, followed by a SC glucagon bolus that was administered when PG was 3.9 mmol/l. The simulation of one experiment lasted for 10 hr after the insulin bolus. The individual insulin bolus size was chosen to achieve a predefined insulin level at the time of glucagon administration.
Thus, patients received different insulin boluses to achieve the same pre-defined insulin levels, due to differences in insulin PK/PD profiles. For each simulation, one of the following predefined insulin levels was achieved when PG was 3.9 mmol/l: The insulin PK model was used to estimate the actual serum insulin level, which was divided by the individual baseline level before the insulin bolus was given (se/ba-insulin). A linear function of patients' insulin action time was used to estimate IOB as follows:
where Dose insulin is the insulin dose, t is the time since the insulin dose, and IAT is the insulin action time describing the time from the insulin dose to the entire dose is cleared, usually 4-5 hr. Patients' individual IATs are listed in Table S1 . TDD was an average of 7 days. In seven virtual patients, one of 10 boluses of subcutaneous insulin was administered (t = Àx) to decrease PG from 10 mmol/l to below 3.9 mmol/l. The insulin bolus size had to achieve pre-defined insulin levels when PG was 3.9 mmol/l. When PG reached 3.9 mmol/l (t = 0), one of 17 subcutaneous glucagon boluses was administered. Treatment success of each glucagon dose was assessed on whether after peak PG was within 5.0 mmol/l (green line: treatment limit) and 10.0 mmol/l (blue line: hyperglycaemia limit), and whether PG 120 min. after the glucagon bolus was above 3.9 mmol/l (red lines: hypoglycaemia limit).
In all experiments, when PG reached 3.9 mmol/l, one of the following 17 glucagon boluses was administered SC: 25, 50, 75, 100, 125, 150, 175, 200, 250, 300, 400, 500, 1000, 1500, 2000 or 2500 lg.
Treatment assessment.
For each experiment, the success of a glucagon dose in treating mild hypoglycaemia but avoiding rebound hyperglycaemia was evaluated based on three criteria: peak PG ≥ 5.0 mmol/l (PG ≥ 5), peak PG ≤ 10.0 mmol/l (PG ≤ 10) and PG ≥ 3.9 mmol/l for 120 min. after the glucagon bolus (PG 120 ≥ 3.9) ( fig. 1 ). The success rate of a glucagon bolus in achieving each of these criteria was calculated at various insulin levels. For each combination of glucagon dose and insulin level, the overall treatment success was calculated as a weighted harmonic mean (H) of the three criteria:
where S is the success rate, equal to the number of subjects fulfilling a criterion divided by the total number of subjects. Arbitrarily, the weighted harmonic mean prioritizes the criteria for peak PG (PG ≥ 5 and PG ≤ 10) higher than the PG level 2 hr after dose (PG 120 ≥ 3.9), as we consider the acute rescue of hypoglycaemia and the avoidance of rebound hyperglycaemia to be more important than the duration of the antihypoglycaemic effect. For each insulin level, the lowest glucagon dose with the highest H-value was the optimum bolus. 4) . The proportion of patients achieving the criterion of PG ≥ 5 (green line) and of PG 120 ≥ 3.9 (red line) increased with increasing glucagon doses. The curves for the PG ≥ 5 criterion were left-shifted compared to the curves for the PG 120 ≥ 3.9 criterion, meaning that less glucagon was needed to fulfil the criterion of PG ≥ 5.0 compared to PG 120 ≥ 3.9. On the other hand, the proportion of patients avoiding rebound hyperglycaemia, PG ≤ 10, declined with increasing glucagon doses (blue line). For instance, when patients had a PG of 3.9 mmol/l and IOB of 1.5 U, a glucagon dose of 100 lg would increase PG ≥ 5.0 mmol/l in <60% of patients, keep PG ≥ 3.9 mmol/l for 2 hr in more than 40% of patients, and keep PG ≤ 10.0 mmol/l in all patients.
Results
Fig . 5 shows the optimum glucagon dosing regimens for treatment of mild hypoglycaemia in the virtual population as a function of insulin levels extracted from figs 2-4 (vertical black lines). The relationship between insulin level and the corresponding optimum glucagon dose could be approximated by an exponential function, regardless of the method used for estimating insulin levels: A 125-lg glucagon dose was needed to optimally treat mild hypoglycaemia when insulin levels were equal to baseline levels. In contrast, glucagon doses >500 lg were needed when serum insulin exceeded 2.5 times baseline insulin concentrations, IOB was above 2.0 U or IOB/TDD was above 6%.
Discussion
In this in silico study, we used a validated PK/PD model to develop optimum glucagon dosing regimens to treat mild hypoglycaemia at varying levels of serum insulin ratio (i.e. the actual serum insulin level divided by patients' baseline insulin level before the insulin bolus), 'insulin on board' and percentage of 'insulin on board' to total daily insulin use in patients with type 1 diabetes. As expected, the antihypoglycaemic effect of glucagon was highly dependent on ambient insulin levels. El Youssef et al. [12] previously showed this relation in vivo by quantifying the glycaemic effects of glucagon at various insulin levels. Notably, the PK/PD model used in the present study was able to replicate the findings by El Youssef et al. with simulations [20] . Furthermore, the PD model was validated using data from another crossover in vivo study with three different SC injections of glucagon for treatment of insulin-induced mild hypoglycaemia [17] . Therefore, we consider the model to be valid for estimating the optimum glucagon dose for treatment of mild hypoglycaemia at varying levels of insulin.
The strength of in silico studies is the ability to simulate large-scale crossover trials that are not feasible in real-life settings. In this study, we estimated the optimum glucagon dose at varying insulin levels based on virtual patients, each undergoing 170 crossover visits per study, resulting in 510 simulations per patient. We defined an optimum glucagon dose to increase PG from 3.9 mmol/l to a peak between 5.0 and 10.0 mmol/l, and sustain PG above 3.9 mmol/l for at least 120 min. after the glucagon bolus. These success criteria were arbitrarily set as no consensus exists regarding post-rescue glucose excursions or post-prandial glucose excursions [21] . We based our criteria on the recommendations of American Diabetes Association [22] that were considered clinically reasonable in most patients. However, not all criteria could be achieved in all patients with the same glucagon dose. We considered the acute rescue of mild hypoglycaemia and the following avoidance of rebound hyperglycaemia to be more important than the duration of the antihypoglycaemic effect. This priority of peak PG over the 2-hr PG level was applied because patients will benefit from the acute rescue and still have time to avoid subsequent hypoglycaemia by suspending their insulin infusion and/or consuming carbohydrates. Alternatively, not reported here, a second bolus of glucagon could be given which has shown to give similar glucose response as the first glucagon bolus [23] .
The glucagon dosing regimens were stratified in relation to different methods of estimating ambient insulin levels. We included IOB because no real-time monitors of serum insulin concentrations are currently available [24] . For decades, insulin pumps with bolus calculators have used IOB feedback as standard to prevent insulin stacking. Depending on the Proportion of patients achieving treatment criteria as a function of glucagon dose, stratified by actual to baseline serum insulin concentrations. Treatment criteria were achieved if glucagon could increase PG to a peak above 5 mmol/l (green line) and below 10 mmol/l (blue line), and keep PG above 3.9 mmol/l for 120 min. after the glucagon bolus (red lines). The optimum glucagon dose for each serum insulin level (black vertical line) was chosen as the lowest dose yielding the maximal weighted success rate of the three treatments criteria.
manufacturer, the bolus calculators estimate IOB differently, that is using a linear or a curvilinear time profile [14] . Most bolus calculators use a curvilinear time profile because it resembles the insulin time-action profile [14] . However, we chose the linear approach due to the unambiguous implementation compared with the curvilinear functions. Further, we consider the differences in IOB time profiles to be negligible for the success of glucagon treatment.
In this study, we found an exponential relationship between the optimum glucagon doses to treat mild hypoglycaemia and the ambient insulin levels. However, the relationship was approximately linear in ranges of serum insulin from 1 to 2 Fig. 3 . Proportions of patients achieving treatment criteria as a function of glucagon dose stratified by insulin on board (IOB). Treatment criteria were achieved if glucagon could increase PG to a peak above 5 mmol/l (green line) and below 10 mmol/l (blue line), and keep PG above 3.9 mmol/l for 120 min. after the glucagon bolus (red lines). The optimum glucagon dose for each insulin on board (black vertical line) was chosen as the lowest dose yielding the maximal weighted success rate of the three treatment criteria.
times basal insulin levels, IOB from 0 to 2 U and IOB/TDD from 0 to 5%. The lowest glucagon dose to optimally treat mild hypoglycaemia was 125 lg when actual insulin levels were equal to baseline levels, which is in accordance with findings from previous studies [25, 26] . In contrast, at very high insulin levels (se/ba-insulin > 3, IOB ≥ 3 U, IOB/ TDD > 8%), the optimum glucagon doses exceeded the amount (1000 lg) normally used for treating severe hypoglycaemia. Nevertheless, the glucagon rescue dose may still be effective in treating severe hypoglycaemia regardless of ambient insulin levels, as shown in psychiatric patients undergoing insulin shock therapy [27] but may not reach our pre-defined Fig. 4 . Proportion of patients achieving treatment criteria as a function of glucagon dose and stratified by the percentage of insulin on board (IOB) to the total daily insulin dose. Treatment criteria were achieved if glucagon could increase PG to a peak above 5 mmol/l (green line) and below 10 mmol/l (blue line), and keep PG above 3.9 mmol/l for 120 min. after the glucagon bolus (red lines). The optimum glucagon dose for each percentages of insulin on board (black vertical line) was chosen as the lowest dose yielding the maximal weighted success rate of the three treatment criteria.
success criteria. Further, at some point, the estimated optimum glucagon dose was, in our opinion, too high (>500 lg) as treatment option for mild hypoglycaemia, especially due to the increased risk of side effects. In a previous study, a single bolus of 500 lg glucagon tended to cause more nausea than 100 lg glucagon during mild hypoglycaemia [28] . In the present study, we found that 500 lg glucagon was needed if serum insulin was 2.5 times baseline insulin levels, IOB was 2 U, or IOB was 6% of TDD. Therefore, if patients have mild hypoglycaemia, but insulin levels above these critical limits, ingestion of carbohydrates rather than mini-dose glucagon may be a better treatment for restoring PG. It was, however, surprising that high glucagon doses were needed at relatively low insulin levels, especially when considering the data from dual-hormone closed-loop studies [7] . This discrepancy may partly be explained by the increased number of glucagon micro-boluses given and the predicted suspension of basal insulin during closed-loop operation, both helping to restore plasma glucose levels. In our simulation study, only a single glucagon bolus was given and basal insulin rate was not suspended. We applied the same success criteria for optimum glucagon dosing to the results of a previous in vivo dose finding study (Table S1 ). Here, in a comparison of glucagon doses, 200 and 300 lg had almost similar success rate to restore mild hypoglycaemia with serum insulin levels 1.9 times higher than baseline levels or with an average IOB of 0.9 U, equivalent to 2.5% of TDD. The lowest optimum dose was similar to the dose suggested in the current in silico (fig. 5 ).
This study has limitations. Firstly, the glucagon dose regimen was based on a simulation model, which may not completely capture real-life events. Secondly, the model parameters were based on an in vivo study with glucagon doses from 100 to 300 lg given to treat mild hypoglycaemia when ambient insulin levels were 0.19-2.3 U of IOB, 0.7-6.1% of IOB/TDD and 1.2-2.9 times the baseline concentrations. Therefore, the simulations with glucagon doses greatly exceeding 300 lg should be interpreted with caution, as should simulations at insulin levels greater than those used for the model building. Thirdly, the used patient sample may not be transferable to a large-scale population, as our virtual population only consisted of seven lean and well-controlled patients and the results may differ in other patients with type 1 diabetes. Therefore, each patient may benefit from adjusting the glucagon dosing regimen to account for, that is glucagon sensitivity [29] . Further, the glucagon doses used were pre-defined and categorically analysed, meaning the 'real' optimum glucagon dose may be between the doses tested in this study. The validated model is based on human inpatient studies and does not account for conditions that might affect insulin sensitivity or glucagon efficacy, that is low-carbohydrate diet [28] , alcohol, exercise [30] and 'stress'. Finally, the model has only been validated in lean patients with type 1 diabetes. As the optimum glucagon dose was not weight-adjusted, the responses may be different in an obese population. To our knowledge, no studies have found a significant effect of weight on the glucose response to glucagon in patients with type 1 diabetes.
Glucagon is currently only available in 1-mg vials and has to be reconstituted immediately before use. At the moment, the proposed glucagon approach to treat mild hypoglycaemia may not be feasible due to duration of reconstituting and injecting glucagon in the accurate dose during hypoglycaemiainduced cognitive impairment. However, stable soluble ). The optimum glucagon dose to restore plasma glucose for each insulin level was chosen as the lowest glucagon dose yielding the maximal weighted success rate of the three treatment criteria (1) to increase PG above 5 mmol/l, (2) to have a peak PG below 10 mmol/l. glucagon formulations may soon be on the market, and minidosing of glucagon to treat mild or impeding hypoglycaemia may be of interest in the future. Hypothetically, an advanced bolus calculator integrated with a continuous glucose monitor advising for insulin injections, carbohydrate intake and glucagon injections could account for side effects, treatment success and IOB, providing the best option for prevention and treatment of hypoglycaemia and leading to improved glucose control. Whether the open-loop system improves quality of life cannot be drawn from this simulation study. Furthermore, as the proposed glucagon dosing regimen is based on reconstituted GlucaGenâ from Novo Nordisk, the model parameters of the simulation model may need adjustments to describe other glucagon products.
To our knowledge, this is the first study to propose a dosing regimen of glucagon in an open-loop setting using simulations. The focus has primarily been on the closed-loop dualhormonal settings in which micro-doses of glucagon were frequently given to prevent hypoglycaemia [5] . This frequent administration cannot be applied in open-loop settings due to inconvenience of multiple glucagon injections. Rather, we consider low-dose glucagon as an alternative to oral carbohydrate intake in treatment of mild hypoglycaemia. We can only speculate that low-dose glucagon treatment, in combination with an advanced bolus calculator, may provide more predictable glucose responses than oral carbohydrate ingestion in treatment of mild hypoglycaemia and may also reduce the risk of over-eating and post-rescue hyperglycaemia.
In conclusion, we used a mathematical PK/PD model to develop insulin-dependent optimum glucagon dosing regimens for treatment of insulin-induced, mild hypoglycaemia. The glucagon doses depend on insulin levels evaluated as serum insulin concentration normalized to basal, insulin on board and ratio of insulin on board to TDD. The regimens were based on simulations of glucagon doses ranging from 25 to 2500 lg and insulin doses yielding pre-defined insulin levels when blood glucose reached the hypoglycaemia threshold. The next step is to evaluate the proposed glucagon dosing regimen in a clinical trial including different phenotypes of patients with type 1 diabetes.
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